W.L. Gore & Assoc. said today that it acquired stealthy Pipeline Medical Technologies and its mitral repair program for an undisclosed amount.
Santa Rosa, Calif.-based Pipleline is developing a transcatheter device designed to duplicate the efficacy and outcomes found when mitral valve chords are repaired via open heart surgery. Gore said it plans to run the company as a wholly owned subsidiary under the Pipeline brand.
“The addition of Pipeline’s investigational technology and talented associates bolsters our continued ambition to improve patients’ lives by offering physicians innovative treatment solutions across the cardiac space,” Gore Medical Products leader David Abeyta said in prepared remarks. “Pipeline’s cutting-edge repair procedure, for patients with mitral valve disease, has the potential to expand Gore’s growing portfolio of treatments for structural heart disease, and it echoes our commitment to innovation across cardiac therapies.”
“We see an array of synergies working with Gore. The company is well recognized for its advanced material capabilities. Its long history of designing solutions for [degenerative mitral regurgitation] treatment challenges already includes the Gore-Tex suture for chordae tendineae, used in surgical chordal repairs and we are excited to collaborate on future innovations in transcatheter mitral chordal repair,” added Pipeline founder Dr. Steven Bolling. “Together we aspire to significantly advance DMR patient outcomes and improve recovery speed.”
“An entirely catheter-based, transfemoral and transseptal chordal repair will be an important tool for minimally invasive treatment of mitral regurgitation,” noted Dr. Paul Sorajja of the Minneapolis Heart Institute.